New antibiotics needed for C. difficile as promising drug abandoned

A final line has been drawn under cadazolid as an initially promising but ultimately disappointing treatment for the management of C. difficile infections. The IMPACT 1 and 2 trials of the novel quinoxolidinone antibiotic versus vancomycin, published together in The Lancet Infectious Diseases, failed to show overall superiority of cadazolid over vancomycin. “Further commercial development ...

Already a member?

Login to keep reading.

© 2021 the limbic